REPLIGEN CORP RGEN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
6/9
Piotroski F — financial health
5.48
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $738.3M | $48.9M | — | $93.9M | $2.1B |
| 2024 | $634.4M | -$25.5M | — | $149.7M | $2.0B |
| 2023 | $632.4M | $35.6M | — | $77.7M | $2.0B |
| 2022 | $801.5M | $186.0M | — | $87.2M | $1.9B |
| 2021 | $670.5M | $128.3M | — | $51.9M | $1.8B |
| 2020 | $366.3M | $59.9M | — | $40.2M | $1.5B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Garland Jason K | CFO | 2026-06-25 | Sell | 733 | $145.00 |
| Madaus Martin D | director | 2026-05-14 | Grant | 995 | — |
| Konstantinov Konstantin | director | 2026-05-14 | Grant | 995 | — |
| EGLINTON MANNER CARRIE | director | 2026-05-14 | Grant | 995 | — |
| Mhatre Rohin | director | 2026-05-14 | Grant | 995 | — |
| Pax Margaret | director | 2026-05-14 | Grant | 995 | — |
| MUIR GLENN P | director | 2026-05-14 | Grant | 995 | — |
| DAWES KAREN A | director | 2026-05-14 | Grant | 995 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.48 (safe)
- Working capital / assets 0.34
- Retained earnings / assets 0.155
- EBIT / assets 0.019
- Equity / liabilities 2.497
Source: SEC EDGAR filings · CIK 0000730272 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.